VCYT Veracyte Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: VCYT

Price (delayed)

$49

Market cap

$3.94B

P/E Ratio

34.03

Dividend/share

N/A

EPS

$1.44

Enterprise value

$3.68B

?
Relative Growth: Rel. Growth: 90
Relative Strength: Rel. Strength: 84
Relative Valuation: Rel. Valuation: 52
Relative Profitability: Rel. Profitability: 93

Veracyte is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide ...

Highlights
The company's quick ratio has surged by 77% YoY
The stock's price to earnings (P/E) is 35% less than its last 4 quarters average of 52.0
Sector: Healthcare
Industry: Biotechnology
Website: http://www.veracyte.com
Peers: MYGN CYTK

Key stats

What are the main financial stats of VCYT

VCYT stock price

How has the Veracyte stock price performed over time
Intraday
-2.02%
1 week
1.66%
1 month
6.96%
1 year
35.81%
YTD
16.39%
QTD
6.43%

Financial performance

How have Veracyte's revenue and profit performed over time
Revenue
$561.9M
Gross profit
$402.96M
Operating income
$105.77M
Net income
$114.48M
Gross margin
71.7%
Net margin
20.4%
The operating income has grown by 36% from the previous quarter
The operating margin has grown by 31% from the previous quarter
Veracyte's net income has increased by 30% QoQ
The net margin has grown by 26% from the previous quarter

Price vs fundamentals

How does VCYT's price correlate with its fundamentals

Growth

What is Veracyte's growth rate over time

Valuation

What is Veracyte stock price valuation
VCYT P/E details
P/E
34.03
P/B
2.82
P/S
6.97
EV/EBIT
31.7
EV/EBITDA
26.33
EV/Sales
6.55
The stock's price to earnings (P/E) is 35% less than its last 4 quarters average of 52.0
The EPS has increased by 30% since the previous quarter
The P/B is 48% above the 5-year quarterly average of 1.9 and 13% above the last 4 quarters average of 2.5
The equity has grown by 14% YoY and by 3.3% from the previous quarter
The P/S is 18% above the 5-year quarterly average of 5.9 and 12% above the last 4 quarters average of 6.2
Veracyte's revenue has increased by 17% YoY and by 3.7% QoQ

Efficiency

How efficient is Veracyte business performance
The ROA has grown by 27% from the previous quarter
The company's return on equity rose by 25% QoQ
The return on sales has increased by 23% since the previous quarter
VCYT's return on invested capital is up by 16% since the previous quarter

Dividends

What is VCYT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for VCYT.

Financial health

How did Veracyte financials performed over time
The company's quick ratio has surged by 77% YoY
The company's current ratio has surged by 69% YoY
The debt is 97% less than the equity
VCYT's debt to equity is down by 25% year-on-year
The debt has contracted by 21% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.